Gemcitabine cisplatin nasopharyngeal

Author: gbxp

August undefined, 2024

WebOct 3, 2024 · This is a phase II clinical trial to evaluate the efficacy and safety of TQB2618 injection combined with Penpulimab in patients with recurrent/metastatic nasopharyngeal carcinoma. This study is divided into two parts. The first part includes the safe introduction phase and the expansion phase. WebSep 3, 2024 · In a recently published phase III clinical trial, gemcitabine (GEM) plus cisplatin (DDP) induction chemotherapy significantly improved recurrence-free survival …

Frontiers The Most Efficacious Induction Chemotherapy Regimen …

WebGEMCITABINE-CISPLATIN is used to treat: Biliary tract cancer. Bladder cancer. Cervical cancer. Malignant mesothelioma. Non-small cell lung cancer (NSCLC). Ovarian cancer. … WebJul 16, 2024 · Nasopharyngeal carcinoma (NPC) is a malignant tumor that occurs in the roof and side walls of the nasopharyngeal cavity, and the incidence rate is the first among otorhinolaryngology malignant tumors. Common clinical symptoms are nasal congestion, blood in the snot, ear stuffiness, hearing loss, diplopia, and headache. highrt paif acount

Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic ...

WebAug 2, 2024 · This study is to evaluate the efficacy and safety of toripalimab and capecitabine maintenance therapy in patients with metastatic nasopharyngeal carcinoma (NPC) after first-line gemcitabine/cisplatin combined with toripalimab. Patients received a standard dose of toripalimab combined with gemcitabine/cisplatin every 3 weeks … WebOnly a few case reports exist in literature about gemcitabine-induced cardiomyopathy. 13–15 Gemcitabine-associated peripheral edema is seen in 20% of patients, cardiac … WebMay 30, 2024 · Gemcitabine/cisplatin became the standard first-line treatment regimen for advanced NPC in 2016 based on a randomized phase III trial that showed that gemcitabine/cisplatin prolonged median PFS compared with fluorouracil/cisplatin. 2 Of note, however, the PFS benefit usually drops precipitously following the completion of six … small seconds watch

Anti‐epidermal growth factor receptor monoclonal antibody plus ...

WebGemcitabine and cisplatin (GP) or docetaxel, cisplatin, and 5-fluorouracil (TPF) regimens are the preferred IC regimens for NPC in the current NCCN guidelines [10]. ... SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. WebOct 28, 2024 · Patients in experimental arm will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. highrule geneticsWebJun 16, 2008 · The aim of the study is to assess if gemcitabine in combination with carboplatin as 1st line chemotherapy in patients with metastatic or recurrent nasopharyngeal carcinoma has reasonable efficacy and a favourable toxicity profile that warrants further comparative study. small secretary desk carved

"Webgemcitabine/cisplatin as an induction therapy option for stage III/IVB nasopharyngeal carcinomas. Based on the data in the noted reference and discussion, the panel consensus was to include gemcitabine/cisplatin as a preferred induction/sequential therapy option for nasopharyngeal cancer. The panel consensus supported a category 1 recommendation. " - Gemcitabine cisplatin nasopharyngeal

Gemcitabine cisplatin nasopharyngeal

Gemcitabine plus cisplatin versus fluorouracil plus …

WebOct 10, 2024 · Gemcitabine plus cisplatin should be considered a preferred front-line option for these patients. Among patients with previously untreated advanced nasopharyngeal carcinoma, those who receive GP have longer OS than those receive FP. Gemcitabine plus cisplatin should be considered a preferred front-line option for these … WebApr 6, 2024 · This was a multi-center, single-arm study that enrolled MIBC patients with a clinical stage of T2-4aN0-1M0, and scheduled for RC. Patients received three 21-day cycles of camrelizumab 200 mg on day 1, gemcitabine 1000 mg/m 2 on day 1 and 8, and cisplatin 70 mg/m 2 on day 2, followed by RC. The primary endpoint was pathologic …

Did you know?

WebMar 31, 2024 · Nasopharyngeal cancer usually presents as locally advanced stage III or IV disease with T3-4 or N2-3 nodal status.The standard of care of patients with locally advanced NPC is concurrent cisplatin chemotherapy with radiation therapy. WebGEMCITABINE-CISPLATIN (jem-SY-tuh-been-sis-PLA-tin) This chemotherapy combination contains the drugs gemcitabine and cisplatin. Combinations usually work better than single drugs because different drugs kill cancer cells in different ways. Drugs in the GEMCITABINE-CISPLATIN combination: Gemcitabine Hydrochloride Cisplatin

WebSelect search scope, currently: articles+ all catalog, articles, website, & more in one search; catalog books, media & more in the Stanford Libraries' collections; articles+ journal articles & other e-resources WebDec 9, 2024 · 1. INTRODUCTION. Nasopharyngeal carcinoma (NPC) is a malignant tumor with geographic characteristics. It has a low incidence in most of the world, but it is more common in southern China and Southeast Asia. 1 According to the data of GLOBOCAN in 2024, there were 133,354 new cases of NPC and 80,008 deaths worldwide. Among …

WebJun 3, 2024 · Leong SS, Wee J, Rajan S, et al. Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. Cancer. 2008;113:1332–7. CrossRef CAS PubMed Google Scholar. Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin … WebThe combination of camrelizumab plus gemcitabine and cisplatin has a manageable toxicity profile and promising preliminary antitumour activity for this disease in treatment-naive patients. Randomised controlled trials are needed to further establish the role of immune checkpoint inhibition for nasopharyngeal carcinomas. Funding:

WebOct 16, 2024 · Allergic to monoclonal antibodies, any camrelizumab components, gemcitabine, cisplatin and other platinum drugs; Prior therapy as follow: Anti-PD-1 or anti-PD-L1; Received last dose of anticancer therapy (including chemotherapy, radiotherapy, targeted therapy, etc.) within 4 weeks of the first dose of study medication;

WebSep 2, 2024 · Patients in active comparator arm will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. small secretary desk shakerWebSep 19, 2024 · Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. Y. Zhang and Others. Adding three cycles of induction chemotherapy with gemcitabine and cisplatin to concurrent ... small section bowls highrst rated lego games ps4WebJun 3, 2024 · New Drug Toripalimab Improves Survival in Nasopharyngeal Cancer. A new immunotherapy, toripalimab, has the potential to change practice in the treatment of … small secret security camerasWebAug 1, 2024 · Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III … highrt return on investment asphaltWebAug 20, 2024 · Gemcitabine plus cisplatin significantly improved overall survival (OS) when compared with fluorouracil plus cisplatin in treatment-naïve patients with … small secreted peptidesWebMay 11, 2012 · The present study is a randomized, control, phase II study of locally advanced nasopharyngeal carcinoma (NPC) in Northwest China treated with Gemcitabine plus cisplatin regimen (GP) or Docetaxel plus cisplatin regimen (TP) induction chemotherapy followed by concurrent chemoradiotherapy. small secrets part 2